锌补充对肥胖的影响:一项随机对照临床试验的研究方案
该研究方案拟在斯里兰卡开展为期3个月的随机双盲安慰剂对照试验,纳入80名18-60岁、BMI≥25的肥胖成人,每日补充元素锌20 mg(以硫酸锌形式)或安慰剂,主要结局为体重下降,次要结局包括空腹血糖、血脂指标和血压。
要点
- 该方案为随机双盲安慰剂对照试验,纳入80名BMI≥25的肥胖成人,每日补锌20 mg或安慰剂,为期3个月。
- 主要结局为体重下降,次要结局包括空腹血糖、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和血压。
核心结论
- 该试验方案旨在评估锌补充对肥胖成人减重及代谢风险参数的影响。
研究设计与样本
- 随机双盲安慰剂对照临床试验,在斯里兰卡瓦扬巴大学应用营养系临床实验室开展,为期3个月。
- 共纳入80名18-60岁、男女不限、肥胖(BMI≥25)的受试者,按年龄、性别和BMI分层后以1:1比例随机分配至试验组和安慰剂组。
- 试验药为含元素锌20 mg(以硫酸锌形式)的胶囊,安慰剂胶囊含一水乳糖,每日服用,持续3个月,研究者和受试者均设盲。
- 访视包括筛查(访视0)、基线(访视1)和3个月(访视2)。
主要发现
- 主要结局指标为肥胖受试者的体重下降。
- 次要结局指标包括血糖状态(空腹血糖)、血脂参数(总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇)和血压。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of obesity is escalating alarmingly worldwide, and it is now becoming a rapidly growing epidemic in developing countries. Recent studies have reported that zinc has been implicated in altered lipid markers, insulin resistance and some obesity markers. There is a lack of evidence on zinc as a potential therapeutic agent to reduce weight and improve metabolic parameters in obese adults. The present study is designed to evaluate the effects of zinc supplementation on obese adults in Sri Lanka. Furthermore, we aim to evaluate the effects of zinc supplementation on metabolic parameters in this population. METHODS/DESIGN: This study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a period of 3 months at the clinical laboratory, Department of Applied Nutrition, Wayamba University of Sri Lanka to assess the efficacy of daily zinc 20 mg supplementation in obese subjects. There will be a total of 80 subjects, aged between 18-60 years, of both genders, who are obese (body mass index (BMI) ≥25). Subjects will be stratified according to age, gender and BMI and randomly assigned into the test and placebo groups in a 1:1 ratio. The treatment drug is a capsule containing elemental zinc 20 mg as the active ingredient (as zinc sulphate). The placebo capsule will contain lactose monohydrate. The subjects will receive either zinc capsules or placebo daily for 3 months. The study treatments will be double blinded to both investigator and subject. The visits and the evaluations will be as follows: screening (visit 0), baseline (visit 1) and 3 month (visit 2). The primary outcome will be weight reduction among the obese subjects. Secondary outcome measures include glycaemic status (fasting blood glucose), lipid parameters (total cholesterol, triglyceride levels, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) and blood pressure. DISCUSSION: The trial protocol will aim to establish the effects of zinc supplementation on weight reduction and metabolic risk parameters among obese subjects. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry: SLCTR/2014/020 . Registered on 18 September 2014.
引用
- Rathnayake KM, Silva K, Jayawardena R, et al. Effects of zinc supplementation on obesity: study protocol for a randomized controlled clinical trial. Trials. 2016. PMID: 27814737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。